 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || JNJ-8543 / J&J
New P1 trial, Combination therapy: A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov) - Oct 28, 2024
P1, N=40, Recruiting, Sponsor: Janssen Research & Development, LLC
- | rezetamig (JNJ-8780) / J&J
Trial completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 3, 2024
P1, N=148, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2026 --> May 2025
- ||| JNJ-1493 / J&J
Enrollment open, Trial completion date, Combination therapy: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - Dec 18, 2023
P1, N=70, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2026 --> May 2025 Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
- || rezetamig (JNJ-8780) / J&J
Trial primary completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 6, 2023
P1, N=148, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026 Trial primary completion date: Oct 2023 --> Apr 2025
- ||| JNJ-1493 / J&J
New P1 trial, Combination therapy: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - Nov 18, 2023
P1, N=70, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || rezetamig (JNJ-8780) / J&J
Enrollment closed: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 11, 2023
P1, N=148, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Oct 2023 --> Apr 2025 Recruiting --> Active, not recruiting
- || rezetamig (JNJ-8780) / J&J
Trial primary completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 21, 2023
P1, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: May 2023 --> Oct 2023
- | rezetamig (JNJ-8780) / J&J
Trial completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Apr 13, 2023
P1, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2023 --> Oct 2023 Trial completion date: May 2025 --> Sep 2026
- || rezetamig (JNJ-8780) / J&J
Enrollment change: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 10, 2023
P1, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2025 --> Sep 2026 N=120 --> 200
- | rezetamig (JNJ-8780) / J&J
Trial completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 2, 2022
P1, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
N=120 --> 200 Trial completion date: Mar 2024 --> May 2025
- | rezetamig (JNJ-8780) / J&J
Trial completion date: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 1, 2022
P1, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2024 --> May 2025 Trial completion date: May 2023 --> Sep 2023
- | rezetamig (JNJ-8780) / J&J
Enrollment open: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 7, 2020
P1, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- | rezetamig (JNJ-8780) / J&J
New P1 trial: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Sep 7, 2020
P1, N=120, Not yet recruiting, Sponsor: Janssen Research & Development, LLC